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Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on
human cancer cells
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Department ofHygienic Chemistry, Faculty ofPharmaceutical Sciences, Tohoku University, Aobayama, Sendai 980-77, Japan.
Sunary We have examined the selective cytotoxicity of immunoliposomes containing doxorubicin
(chemoimmunoliposomes, CILs) targeting the c-erbB-2 gene product (gpl85) or gpl25. Anti-gpl85 and
anti-gpl25 CHLs were prepared by conjugation of doxorubicin-containing liposomes with monoclonal
antibodies SER4 (IgG) and HBJ127 (IgG) respectively. Both CILs bound to human SKBr-3 breast cancer cells
and MKN-7 human gastric cancer cells, which express both antigens in high density. The IC50 of anti-gpl85
CILs on protein synthesis by SKBr-3 cells was respectively 2- and 25-fold lower than that of anti-gpl25 CILs
and unmodified liposomes. Furthermore, anti-gpl85 CILs significantly inhibited neither the phytohaemagg-
lutin response of normal lymphocytes nor protein synthesis of gpl85-negative T24 bladder cancer. Quan-
titative analysis of cell-associated doxorubicin revealed that, compared with anti-gpl25 CILs, anti-gpl85 CILs
required. respectively 4.5 and 4.3 times less doxorubicin association in SKBR-3 and MKN-7 cells, for 50%
cytotoxicity. In addition, flow cytometric analysis showed that both SKBr-3 and MKN-7 internalised more
anti-gpl85 CILs and processed them more efficiently than anti-gpl25 CILs. These results suggest that
anti-gpl85 CILs act selectively against gpl85-expressing cancer cells and that gpl85 is a more sensitive antigen
for CIL cytotoxicity associated with endocytosis activity.
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We have previously examined the anti-cancer activity of
doxorubicin-containing immunoliposomes (chemoim-
munoliposomes, CILs) targeting a tumour-associated antigen,
gp125 (Masuko et al., 1985; Suzuki et al., 1994). In general,
the anti-cancer effect of CILs would be expected to be closely
related to their intracellular fate. In these previous reports,
various tumour cells expressing gpl25 were analysed for
endocytosis of and sensitivity to anti-gpl25 CILs. It was
shown that endocytosis was not necessarily required for their
cytotoxicity. However, it is unclear whether these findings
were due to the specific character of gp125 as the target
antigen.
c-erbB-2 is a proto-oncogene that encodes a 185 kDa cell-
surface glycoprotein (Di Fiorre et al., 1987). Amplification
and overexpression of the c-erbB-2 gene has been shown in
many human cancers, including 30% of lung, breast, ovary
and stomach adenocarcinomas. In cases with gene
amplification, there is a 50- to 100-fold increase in c-erbB-2
mRNA as compared with normal cell levels, and this overex-
pression has been correlated with the malignancy of cancer
cells (reviewed in Di Fiorre et al., 1991). Various antibodies
directed against this antigen have been found to have
significant modulatory activity (Drebin et al., 1985; Maier et
al., 1991). Thus gpl85 is thought to be endocytosed and
would thus be a suitable target for CILs.
In this report, we show a selective anti-cancer effect of
CILs targeting gp185 and demonstrate the implications of
endocytosis activity for the CIL effect by comparing the two
CIL preparations targeting gpl85 and gpl25 on human
breast cancer cell line SKBr-3 and the gastric cancer cell line
MKN-7.
Materials and methods
Animals and cells
Male Balb/c mice were obtained from Hamamatsu Farm,
Chiba, Japan, and used at 8 weeks of age. Human cancer cell
lines, including a breast cancer cell line, SKBr-3, a gastric
cancer cell line MKN-7, and a bladder cancer cell line, T24,
were maintained in Dulbecco's modified Eagles minimal
essential medium (Nissui Pharmaceutical, Tokyo, Japan),
2 mM L-glutamine, 1 giM sodium pyruvate, 10 mM Hepes and
60 gig ml-l kanamycin, pH 7.4 (standard medium) containing
10% heat-inactivated fetal calf serum (FCS) (MA Bio-
products, Walkersville, MD, USA), in Costar tissue culture
flasks. Human peripheral blood mononuclear cells (PBMC)
were freshly prepared from blood obtained from a healthy
volunteer by Ficoll (Pharmacia) gradient centrifugation.
Chemicals
Dipalmitoylphosphatidylcholine was obtained from Nichiyu
Liposome, Tokyo, Japan, and dipalmitoylphos-
phatidylethanolamine, cholesterol, MBS and PHA were from
Sigma (St Louis, MO, USA). Doxorubicin hydrochloride
(DOX) was donated by Kyowa Hakko, Tokyo, Japan.
Sepharose CL6B, protein G-Sepharose and SPDP were pur-
chased from Pharmacia Fine Chemicals, Uppsala, Sweden.
FITC was from Dojin Chemical, Tokyo, Japan. MBPE was
prepared as previously described (Hashimoto et al., 1983).
Leucine-free medium was prepared from RPMI-1640 select
amine kit (Gibco, Life Technologies, NY, USA). L-[4,5-
3H]Leucine ([3Hpeucine) and [methyl-3H]thymidine
(J3Hlthymidine) were obtained from Amersham Buckingham-
shire, UK.
MAbs
Mouse MAbs HBJ127 and SER4 (both IgGl) were raised
against a tumour-associated antigen, gpI25, and the c-erbB-2
product, gpI85, respectively (Masuko et al., 1985, 1989).
AL-6 (mouse IgM) was raised against immunoliposomes and
recognised MBPE on liposomes (Suzuki et al., 1992). MAbs
were purified from ascites fluid of mice that had been trans-
planted with the corresponding hybridoma cells by 50%
ammonium sulphate precipitation followed by protein G
affinity chromatography for IgG or gel filtration on
Sepharose CL6B for IgM.
FITC-conjugated AL-6 was prepared for determining cell-
surface CILs, by coupling AL-6 with FITC at a molar ratio
of 1:50. The molar ratio in the product was about 1:12.
Thiolation of IgG was performed by SPDP substitution at a
molar ratio of 1:5 as described by Carlsson et al. (1978). The
Correspondence: S Suzuki
Received 16 January 1995: revised 18 Apnrl 1995; accepted 28 April
1995Im,plcalifo the endocylosis activity
S Suzuki etal
average substitution ratio was 2.8 and 2.3 for SER4 and
HBJ127 respectively.
Preparation ofliposomes
CILs were prepared as previously described (Suzuki et al..
1994). Briefly, a lipid film prepared from a mixture of dipal-
mitoylphosphatidylcholine (25ytmol), cholesterol (17.5 lLmol)
and MBPE (2.5pmol) was suspended in 2 ml of 125 mM
ammonium sulphate, 10 mM Hepes and 2 mM EDTA
(pH 5.2). and was extruded ten times through a 0.1 .tm pore
size polycarbonate membrane at 45'C to form small
umnlamellar liposomes (SULs). The resultant liposome
suspension was chromatographed on a Sepharose CL6B-
packed column (1.6 x 30 cm) equilibrated with Hepes-
buffered saline (HBS) pH 6.8. Liposomes eluting at void
volume were collected, and were then incubated with I mg of
DOX for 1 h at 45°C. The liposomes were separated from
unencapsulated (free) DOX by Sepharose CL6B chromatog-
raphy as described above, and were then incubated with 2 mg
of thiolated IgG for 1 h at 37°C followed by an additional
incubation with 5 gl of 2-mercaptoethanol for 30 min.
Antibody-coated DOX-loaded liposomes (CILs) were
purified by Sepharose CL6B chromatography with HBS
pH 7.4. sterilised by filtration through a 0.2ptm pore size
polycarbonate membrane, and stored at 4'C until use. The
hpid, antibody and DOX contents of liposomes were deter-
mined as described previously (Hashimoto et al., 1983;
Tanaka et al.. 1989). CILs contained 108-136 ILg of antibody
and 25-32fLg of DOX per yimol of total lipid.
Quantitative analysis for CIL association
Adherent cells were detached with 0.0044% actinase. 0.11%
EDTA in PBS for 5 min at 37°C. and were washed once with
ice-cold PBS. Cells were mixed with CILs in a volume of
0.2 ml in standard medium containing 10% FCS and
incubated for 2 h at 4'C. After washing with ice-cold PBS
twice. cells were mixed with 0.3 M hydrochloric acid. 50%
ethanol to extract DOX. and then incubated for 20 min at
37°C. After centrifugation at 500g for 10 mmn. the
fluorescence intensity of DOX (and its metabolites) in the
supernatant was determined fluorometrically at 480nm
(excitation) and 580rnm (emission). An external standard
curve for DOX was drawn by plotting the percentage
recoveries of DOX from control samples mixed with known
doses of DOX.
Flow cltometric analysisfor cell-surface CILs
Cells were treated with CILs in standard medium containing
IO% FCS for 2 h at 4'C with vortexing at 15 min intervals.
Cells were washed twice with ice-cold PBS, and reincubated
for 0-2 h at 37'C in standard medium containing 10% FCS.
After washing as above. cells were treated with FITC-AL-6
(50 Lg ml-') for 1 h at 4'C. After washing twice, cell
fluorescence was analysed by a FACScan flow cytometer
(Becton Dickinson. Mountain View, CA. USA) with excita-
tion at 488 nm and emission at 515-545 nm. The
fluorescence intensity of 10 000 viable cells was recorded. All
determinations were done at the same detection sensitivity.
The mean fluorescence intensity of each sample was com-
puted.
Analysisfor processing ofCILs by cell
Processing of CILs bv cells was determined by flow
cytometry on the basis of intracellular fluorescence of
liposomal DOX as described below. As the fluorescence of
DOX encapsulated in CILs is self-quenched at high concent-
rations, its dilution results in augmentation of the
fluorescence signal (dequenching). Thus, when CILs are
endocytosed by cells and are released into an acidic environ-
ment in endosomes or lysosomes. DOX (a lipophilic weak
base) will leak from them. resulting in dilution and an inc-
rease of fluorescence inside cells.
Cells were treated with CILs for 2 h at 4'C. washed with
ice-cold PBS. resuspended in standard medium containing
10% FCS and incubated for various times at 37°C. Cell
fluorescence was then measured by flow cytometry as des-
cribed above except for detection at FL2 range (emission at
545-590 nm).
Anal}sisfor c}totoxicitv ofCILs
The cytotoxic activities of CILs were determined by assaying
the inhibition of protein synthesis on cancer cells. [iH]
Leucine but not [3H]thymidine incorporation highly cor-
related with the viable cell number after the treatments as
estimated by trypan blue staining. This measurement
therefore also includes cytostatic effects.
Reciprocal dilutions of free DOX solution. CILs or CL
suspension (100jd) and I x l0W cells suspended in 100 tL of
standard medium containing 10% FCS were mixed in a test
tube and incubated for 30 min at 37°C. The cells were
washed twice with standard medium, centrifuged at 200g for
5 mmn, and resuspended in 1 ml of standard medium contain-
ing 10% FCS. Aliquots of the cell suspension were dist-
ributed in quadruplicate into a Falcon flat-bottomed 96-well
tissue culture plate (4 x I03 cells per well). and then cultured
in 200 IL of fresh standard medium containing 10% FCS for
3 days in a humidified carbon dioxide incubator. After the
culture period. supernatant was discarded, cells in each well
were starved of leucine by incubation with leucine-free
medium (100ILI) for 2 h. pulsed with [3Hjleucine (0.5glCi per
well) for an additional 4 h. and then harvested by
actinase-EDTA treatment. The radioactivity of the cells was
measured by standard liquid scintillation counting. In the
case of Figure 3. the residual cells (840 tLI of cell suspension)
were also collected by centrifugation and fluorometrically
analysed for DOX association.
Anal sisfor PHA response ofPBMCs
The cytotoxic activities of drugs on normal PBMCs were
determined by assaying the inhibition of their PHA response.
PBMCs (2.0 x 106) were mixed with free DOX solution, CILs
or CL suspension in 200gAl of standard medium for 30 min at
37C. After washing twice with ice-cold standard medium,
cells were seeded at 2.5 x lIW cells per well in quadruplicate
into a Falcon flat-bottomed 96 well-tissue culture plate, and
cultured in 200glI of standard medium containing 10% FCS
and PHA at 20gig ml-'. After 3 days' culture, cells were
pulsed with [3H]thymidine (0.5 itCi per well) for 4 h, and then
harvested. The radioactivity of the cells was measured by
standard liquid scintillation counting.
Results
Binding of SER4 CILs (anti-gpl85 CILs) was analysed on
SKBr-3 and MKN-7 cells, which expressed both gpl85 and
gpl25, T24 cells, which expressed only gpl25 (almost gpl85-
negative tumour cells), and PBMCs (antigen-negative normal
cells) and compared with HBJ127 CILs (anti-gpl25 CILs),
CLs or free DOX (Figure 1). Among the four cell types,
SER4 CILs selectively bound to SKBr-3 and to MKN-7 at a
level 2.8 times lower than to SKBr-3. HBJ127 CILs bound to
all three cancer cells: T24, SKBr-3 and MKN-7. Both CILs
showed far weaker binding to PBMCs. at almost the same
level as that of CLs and free DOX, which showed back-
ground levels. The amount of bound SER4 CILs was 2.5 and
5.9 times less than the amount of HBJ127 CILs in SKBr-3
and MKN-7 respectively. As this binding analysis was done
under saturating conditions (data not shown), the results
represent the binding capacacity of each CIL on the target
cells.
In a cytotoxicity analysis. SER4 CILs inhibited protein
synthesis of SKBr-3 in a dose-dependent manner with an IC50of 0.8
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fig ml-1 DOX (Figure 2a, open triangles). This among three cancer cells were almost the same
ic activity was completely blocked by competition (0.45-0.62 g ml-' DOX) but slightly lower than that for
:cess intact SER4 MAb (Figure 2a, closed triangles), PBMCs (1.3 ig ml-'). CLs showed only weak cytotoxicity
strating the specificity of SER4 CILs. This specificity against all four target cells. Especially in the case of SKBr-3,
,o confirmed by the far lower ICR, of SER4 CILs for HBJ127 CILs, which had shown higher binding capacity to
Us and PBMCs (18 and 12iLg mrl respectively; Figure SKBr-3 (Figure 1), showed relatively low cytotoxic potential
d). SER4 CILs show selective cytotoxicity also on (IC50 1.5l1gml; Figure 2b) compared with SER4 CILs.
7. but to a lesser degree than on SKBr-3 (IC50, Thus, cell-associated DOX at each dose in Figure 2a and b
nl-' in Figure 2b). The IC50 values of free DOX was quantified to reveal the amount of DOX required for
50% inhibition of [3H]leucine incorporation (Figure 3). In the
case of SKBr-3 cells, it was 1 x 108 DOX molecules per cell
for SER4 CILs, which was 4.5 times lower than that required
for HBJ127 CILs (Figure 3a). Similar results were obtained
for MKN-7 cells, the concentration required being 4.3 times
sN-7zgrX,X,,.,,,,.,. U .............. ,.lower for SER4 CILs than for HBJ127 CILs (Figure 3b).
We then demonstrated endocytosis of CILs by SKBr-3 and
MKN-7 cells (Figure 4). When SKBr-3 cells were coated with
lmc CILs at 4°C and reincubated at 37C (Figure 4a), both CILs
on the cell surface were decreased over an increasing incuba-
tion time, but the initial rate of decrease was higher for
SER4 CILs (64%/10 min) than for HBJ127 CILs (30%/
Br-3 10 min). Also, on MKN-7 cells, the amount of SER4 CILs
bound on the cell surface decreased faster than HBJ127
4 CILs, but slightly less efficiently than on SKBr-3 cells (Figure
4b). Under the same conditions as Figure 4, decrease of
T24 cellular DOX content was within 5% of the initial value in
T24 v/g//////,//g/X///X///////X//X/,g,/,//S,,/ ,} i both cell lines (data not shown). Thus, such decreases suggest
, the internalisation of CILs by endocytosis as this process was
0 1 2 3 4 5 inhibited with ammonium chloride, chloroquine and col-
Associated (x 10 8 molecules per cell) chicine (data not shown) (Bennstein et al., 1987; Collins et
e 1 Binding of CILs to target cells. Cells (2 xlO5 for al.. 1989).
-3, MKN-7 and T24. 2 x 106 for PBMCs) were mixiied with We further analysed processing of both CILs using flow
)OX (_), SER4 CILs. (L]), HBJl27 CILs ( V) or cytometnc techniques. As shown in Figure 5a, dequenching
(E) at a final DOX concentration of 30 jg ml-'.After of DOX fluorescence on SKBr-3 cells was observed in SER4
icubation at 4°C, cell-associated DOX was quantified as CILs by about 270%, but was not found for HBJ127 CILs.
bed in Materials and methods. Columns and bars are the Under fluorescence microscopy, at time 0 in Figure 5a, DOX
and s.e., respectively, from three determinations. fluorescence of SER4 CILs was observed as ring shapes.
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Fiugre 2 Effect of CILs on protein synthesis of tumour ceUs and proliferation of PBMCs with PHA. CeUs treated with free DOX.
CLs or CILs in various DOX concentrations were analysed for their ['H]leucine (a, b and c) or [3H]thymidine (d) incorporation
activity as described in Materials and methods. The percentage of mean incorporation of radioisotope as compared with
non-treated ceUls (control) is shown. Symbols represent the average values from four determinations. All s.e. values were less than
8.8% of control. (a) SKBr-3. (b) MKN-7. (c) T24. (d) PBMCs. *, Free DOX; 0, CLs; 0, HBJ127 CILs; A, SER4 CILs; A,
SER4 CILs with excess (1 mgml-') SER4 MAbs.
w~~~~~~~~ - -- w*fsrT
.... |Imlpir-in fwrtoeadorc$si -cf
S Suuki et a
666
2 4
b
I , * I I 1 1
6 8 0 2 4
DOX association ( x 10-8 molecules per cell)
Figure 3 Inhibition of protein synthesis by SER4 CILs (A) and HBJ127 CILs (0) on SKBr-3 (a) and MKN-7 (b) cells depending
on DOX association. During the analysis described in Figure 2 the amount of DOX associated with cells was concomitantly
analysed using residual cell suspensions. Plots for cell-associated DOX vs per cent [3Hpeucine incorporation are shown.
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Fge 4 Down-modulation of cell-surface CILs at increasing incubation times. Intact (open symbols) or formalin-fixed (closed
symbols) cells were incubated with CILs (0.2 mm lipid) for 2 h at 4°C, washed twice with ice-cold PBS, and reincubated in standard
medium containing 10% FCS for the indicated period at 3TC. Cells were then treated with FITC-AL-6 and processed for flow
cytometry as described in Materials and methods. Per cent mean fluorescence intensities as compared with the values at time 0 are
shown. Symbols and bars represent the mean values and s.e. of the mean, respectively, from three determinations. (a) SKBr-3. (b)
MKN-7. 0, *, HBJ127 CILs; A, A, SER4 CILs.
indicating localisation on the cell surface. At 1 h it was found
to be brighter and was observed in small dots beneath the
cell membrane or near the nucleus, probably indicating
localisation in endosomes or lysosomes. On the other hand
using HBJ127 CILs after I h incubation, the fluorescence was
observed both on the cell surface and as intracellular dots
with a similar intensity. Under the same conditions MKN-7
showed only weak processing of SER4-CIL (Figure 5b).
Discussio
We first examined the potential of anti-gp185 CILs (SER4
CILs) for therapeutic application. Since gpl85 is also exp-
ressed on normal cells, although at a far lower level, the
magnitude of the therapeutic efficacy is based on the degree
of overexpression of gp185 on the target cancer cells. As
shown in Figure 1, SER4 CILs showed higher binding to
SKBr-3 and MKN-7 which overexpressed gpl85, than to the
control cancer cell T24 and normal PBMCs. SER4 CILs also
showed cytotoxicity to SKBr-3 and MKN-7 cells in an
antigen-dependent manner, but showed only limited toxicity
against T24 cells and normal PBMCs. Although the findings
presented in this paper represent only the first step in further
application of CILs, the selective cytotoxicity against SKBr-3
and MKN-7 in conjunction with results discussed below
suggests the potential of SER4 CILs for therapeutic applica-
tion. In particular, when CILs were injected i.v. into a
mouse, the (liposomal) DOX clearance rate was 12 times
longer than that of free DOX (our unpublished data), sugges-
ting superior in vivo pharmacokinetics of CILs for cancer
therapy as compared with free DOX.
We next examined the dependency of CIL endocytosis on
CIL cytotoxicity by comparing the two CILs targeting
different antigens, gpl85 and gpl25, on the same target cells.
As shown in Figure 3a, the amount of SER4 CILs associated
with SKBr-3 was smaller than HBJ127 CILs at all doses
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Fure 5 Analysis of processing of CILs by cells. Cells were incubated with CILs (0.2 mm lipid) for 2 h at 4°C. washed twice with
ice-cold PBS, and reincubated in standard medium containing 10% FCS for the indicated period at 3rC. Then cells were washed
twice with ice-cold PBS and processed for flow cytometry. Per cent mean fluorescence intensities as compared with the values at
time 0 are shown. Symbols and bars represent the mean values and s.e. of the mean, respectively, from three determinations. (a)
SKBr-3. (b) MKN-7. 0, HBJ127 CILs; A, SER4 CILs.
tested, however SER4 CILs showed stronger cytotoxicity
than HBJ127 CILs comparing the same cellular DOX level
(see results section). When CIL endocytosis by SKBr-3 was
examined, SER4 CILs adhering to the cell surface were 90%
internalised after a 1 h incubation, and were found to be
efficiently processed (Figures 4 and 5), while HBJ127 CILs
were only 60% internalised and were far less processed.
Thus, in the case shown here, endocytosis positively cor-
related with cytotoxic efficiency of CILs, although these
results differ from a previous report (Suzuki et al., 1994).
Processing of CILs might be one of the key factors for the
expression of CIL cytotoxicity as it has been reported that
the cytotoxicity of DOX is dependent on its reduction by
cytosolic enzymes (Bartoszek and Wolf, 1992). Thus, DOX in
SER4 CILs endocytosed by target cells was found to have
leaked out into endosomes, and then probably diffused into
the cytosol resulting in more effective activation than for
HBJ127 CILs. It is still unclear, however, what is the reason
for the different intracellular fate of CILs between gpl85 and
gpl25 as target antigens.
The percentage (90%) internalisation of SER4 CILs is high
compared with that of anti-gp185 MAbs (Drebin et al., 1985;
Maier et al., 1991; our unpublished data), of which only
14-70% were internalised. Thus, targeting in liposomal form
might accelerate the internalisation of the ligand, perhaps
because of multivalent binding (a CIL vesicle contained
30 IgG molecules) or their large size or cell membrane-lipid
interactions.
Taken together, the cytotoxic efficiency of CILs was found
to be dependent not only on antigen density, but also on the
cell type studied and the antigen characteristics, in particular
endocytosis. These considerations are thus important in selec-
ting useful antigens (ligand) for therapeutic application of
CILs.
In conclusion, SER4 CILs showed a selective anti-cancer
effect against gpl85-overexpressing SKBr-3 and MKN-7
cells, and, compared with gpl25, gpl85 was a more sensitive
antigen for CIL cytotoxicity probably as a result of
endocytosis activity.
Abbrevatiof CIL, chemoimmunoliposome, doxorubicin-
encapsulated immunoliposome; CL, chemoliposome, unmodified
liposome containing doxorubicin; DOX, doxorubicin; PBMC,
peripheral blood mononuclear cell; Hepes, N-2-
hydroxyethylpiperazine-N'-2-ethansulphonic acid; MAb, monoclonal
antibody; SPDP, N-hydroxysuccinimidyl-342-
pyridy1dithio)propionate; FITC, fluorescein isothiocyanate; PBS,
phosphate-buffered saline; HBS, Hepes-buffered saline (20 mM
Hepes, 150 mM sodium chloride); MBS, m-
maleimidobenzoyl-N-hydroxysuccinimido ester; MBPE, MBS
derivative of dipalmitoylphosphatidylethanolamine; PHA,
phytohaemagglutinin.
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